原　梓 (ハラ　アズサ)

HARA Azusa

写真a

所属（所属キャンパス）

薬学部 薬学科 医薬品開発規制科学講座 （芝共立）

職名

准教授
このページの先頭へ▲

学位 【 表示 ／ 非表示 】

  • 博士（医療薬学）, 東北大学, 課程, 2009年03月

このページの先頭へ▲

免許・資格 【 表示 ／ 非表示 】

  • 薬剤師免許, 2004年06月

このページの先頭へ▲
 

研究分野 【 表示 ／ 非表示 】

  • 疫学・予防医学

このページの先頭へ▲

研究キーワード 【 表示 ／ 非表示 】

  • 疫学、薬剤疫学

このページの先頭へ▲
 

論文 【 表示 ／ 非表示 】

  • The present situation of home blood pressure measurement among outpatients in Japan

    Noda A., Obara T., Abe S., Yoshimachi S., Satoh M., Ishikuro M., Hara A., Metoki H., Mano N., Ohkubo T., Goto T., Imai Y.

    Clinical and Experimental Hypertension （Clinical and Experimental Hypertension)  42 （ 1 ） 67 - 74 2020年01月

    ISSN  10641963

    　概要を見る

    © 2019, © 2019 Taylor & Francis. Objective: To clarify the present situation of home blood pressure (HBP) measurement among Japanese patients. Methods: A nationwide questionnaire survey regarding HBP measurement was conducted on patients aged 20 years or older who had visited 20 community pharmacies to have their prescriptions filled. Results: In total, 76.7% of 1,103 hypertensives and 40.9% of 1,106 normotensives had their own devices for HBP measurement. Compared with normotensives, a higher proportion of hypertensives recognized the guideline-based reference values for HBP and clinic BP. Compared with hypertensives who did not have a physician’s recommendation, those who did more often had their own devices, recognized the guideline-based reference values for HBP, and measured HBP every day (70.4%, 1.5%, and 31.6% vs. 91.1%, 6.9%, and 65.4%, respectively). Among 793 hypertensives who measured HBP, a higher proportion of those with a physician’s recommendation measured HBP according to optimal guideline-based procedures compared with those without. Among 560 hypertensives who recorded HBP readings, a higher proportion of those with a physician’s recommendation (74.6%) showed all HBP readings to their physicians compared with those without (35.3%). Conclusions: Our findings suggest that physicians should recommend measuring HBP in accordance with the Japanese Society of Hypertension guidelines more aggressively, and provide more detailed explanations to patients regarding how to measure HBP.

  • Age-Related Trends in Home Blood Pressure, Home Pulse Rate, and Day-to-Day Blood Pressure and Pulse Rate Variability Based on Longitudinal Cohort Data: The Ohasama Study

    Satoh M., Metoki H., Asayama K., Murakami T., Inoue R., Tsubota-Utsugi M., Matsuda A., Hirose T., Hara A., Obara T., Kikuya M., Nomura K., Hozawa A., Imai Y., Ohkubo T.

    Journal of the American Heart Association （Journal of the American Heart Association)  8 （ 15 ）  2019年08月

    　概要を見る

    © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. Background: Home blood pressure is a more accurate prognosticator than office blood pressure and allows the observation of day-to-day blood pressure variability. Information on blood pressure change during the life course links the prediction of blood pressure elevation with age. We prospectively assessed age-related trends in home blood pressure, home pulse rate, and their day-to-day variability evaluated as a coefficient of variation. Methods and Results: We examined 1665 participants (men, 36.0%; mean age, 56.2 years) from the general population of Ohasama, Japan. A repeated-measures mixed linear model was used to estimate the age-related trends. In a mean of 15.9 years, we observed 5438 points of measurements including those at baseline. The home systolic blood pressure linearly increased with age and was higher in men than in women aged <70 years. There was an inverse-U-shaped age-related trend in home diastolic blood pressure. The day-to-day home systolic blood pressure linearly increased with age in individuals aged >40 years. However, an U-shaped age-related trend in day-to-day diastolic blood pressure variability with the nadir point at 65 to 69 years of age was observed. No significant sex differences in the day-to-day blood pressure variability were observed (P≥0.22). The average and day-to-day variability of home pulse rate decreased with age but were lower and higher, respectively, in men than in women. Conclusions: The current descriptive data are needed to predict future home blood pressure and pulse rate. The data also provide information on the mechanism of day-to-day blood pressure and pulse rate variability.

  • 患者向け医薬品添付文書「患者向医薬品ガイド」の利活用に向けた製薬企業における認識調査

    土肥　弘久, 伊東　里奈, 原　梓, 浅田　和広, 山本　美智子

    医薬品情報学 21 （ 3 ） 116 - 125 2019年

    研究論文（学術雑誌）, 共著, 査読有り

  • Genome-wide association study for white coat effect in Japanese middle-aged to elderly people: The HOMED-BP study

    Ogata S., Kamide K., Asayama K., Tabara Y., Kawaguchi T., Satoh M., Katsuya T., Sugimoto K., Hirose T., Inoue R., Hara A., Obara T., Kikuya M., Metoki H., Matsuda F., Staessen J., Ohkubo T., Rakugi H., Imai Y.

    Clinical and Experimental Hypertension （Clinical and Experimental Hypertension)  40 （ 4 ） 363 - 369 2018年05月

    ISSN  10641963

    　概要を見る

    © 2018 Taylor & Francis. Background: White coat effect (WCE), the blood pressure (BP) difference between clinical and non-clinical settings, can lead to clinical problems such as misdiagnosis of hypertension. Etiology of WCE has been still unclear, especially from genetic aspects. The present article investigated association between genome-wide single nucleotide polymorphisms (SNPs) and WCE in patients with essential hypertension. Methods: The present cross-sectional analyses were based on 295 Japanese essential hypertensive outpatients aged ≧40 years enrolled in randomized control study, Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP) study, who were not taking antihypertensive medications before the randomization. Home and clinic BP were measured. WCE was defined by subtracting home BP from clinic BP. Genotyping was conducted with 500K DNA microarray chips. Association between genome-wide SNPs and WCE were analyzed. For replication (p < 10–4), we analyzed participants from Ohasama study who took no antihypertension medications and whose SNPs were collected. Results: Genome-wide SNPs were not significantly associated with WCE of systolic and diastolic BP after corrections of multiple comparisons (p < 2 × 10–7). We found suggestive SNPs associated with WCE of systolic and diastolic BP (p < 10–4). However, the consistent results were not obtained in the replication study. Conclusion: The present article showed no significant association between genome-wide SNPs and WCE. Since there were several suggestive SNPs associated with WCE, the present study warrants a further study with bigger sample size for investigating the genetic influence on WCE.

  • Association between amplitude of seasonal variation in self-measured home blood pressure and cardiovascular outcomes: HOMED-BP (Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure) study

    Hanazawa T., Asayama K., Watabe D., Tanabe A., Satoh M., Inoue R., Hara A., Obara T., Kikuya M., Nomura K., Metoki H., Imai Y., Ohkubo T., Arakawa K., Fujishima M., Fujii J., Fukiyama K., Hisamichi S., Iimura O., Ishii M., Omae T., Saruta T., Yoshinaga K., Abe I., Abe K., Abukawa T., Ashida T., Dohba N., Etoh T., Fujimura A., Fujita T., Fukui A., Gotoh T., Hama H., Hano T., Hayashi H., Hayashida N., Hayashi M., Hiramori K., Hirai Y., Hirata Y., Hiwada K., Hora K., Ichikawa S., Iida T., Ikeda T., Imaizumi T., Ishikawa K., Ito I., Ito M., Ito S., Iwaoka D., Kanamasa K., Katagiri T., Katayama S., Kawamura H., Kawano Y., Kida H., Kikuchi K., Kimura G., Kimura K., Kitaoka H., Kobayashi S., Kohara K., Kojima S., Komuro I., Kumagai H., Kumagai Y., Kusano E., Kushiro T., Kuwajima I., Maruyama Y., Masani F., Matsubara H., Matsubara T., Matsumoto M., Matsuoka H., Matsuura H., Mishima Y., Miura M., Miyamori I., Mori H., Murakami H., Muratani H., Nakagawa M., Nakao K., Naruse M., Nishio I., Ogihara T., Ohta M., Ohtsuka K., Ohtsuka Y., Ohuchi Y., Oikawa S., Okabe M., Okumura K., Saitoh I., Saitoh H., Sakata T., Saku K.

    Journal of the American Heart Association （Journal of the American Heart Association)  7 （ 10 ）  2018年05月

    　概要を見る

    © 2018 The Authors. Background--The clinical significance of long-term seasonal variations in self-measured home blood pressure (BP) has not been elucidated for the cardiovascular disease prevention. Methods and Results--Eligible 2787 patients were classified into 4 groups according to the magnitude of their seasonal variation in home BP, defined as an average of all increases in home BP from summer (July-August) to winter (January- February) combined with all decreases from winter to summer throughout the follow-up period, namely inverse- (systolic/ diastolic, < 0/< 0 mm Hg), small- (0-4.8/0-2.4 mm Hg), middle- (4.8-9.1/2.4-4.5 mm Hg), or large- (≥9.1/≥4.5 mm Hg) variation groups. The overall cardiovascular risks illustrated U-shaped relationships across the groups, and hazard ratios for all cardiovascular outcomes compared with the small-variation group were 3.07 (P=0.004) and 2.02 (P=0.041) in the inversevariation group and large-variation group, respectively, based on systolic BP, and results were confirmatory for major adverse cardiovascular events. Furthermore, when the summer-winter home BP difference was evaluated among patients who experienced titration and tapering of antihypertensive drugs depending on the season, the difference was significantly smaller in the early (September-November) than in the late (December-February) titration group (3.9/1.2 mm Hg versus 7.3/ 3.1 mm Hg, P < 0.001) as well as in the early (March-May) than in the late (June-August) tapering group (4.4/2.1 mm Hg versus 7.1/3.4 mm Hg, P < 0.001). Conclusions--The small-to-middle seasonal variation in home BP (0-9.1/0-4.5 mm Hg), which may be partially attributed to earlier adjustment of antihypertensive medication, were associated with better cardiovascular outcomes.

全件表示 >>

このページの先頭へ▲

総説・解説等 【 表示 ／ 非表示 】

このページの先頭へ▲

競争的資金等の研究課題 【 表示 ／ 非表示 】

  • 生活習慣病薬の有効性、安全性およびがん予防効果に関する薬剤疫学の国際共同研究

    2018年04月
    -
    2021年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 橋本　梓, 基盤研究（Ｃ）, 補助金,  代表

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 課題研究（医薬品開発規制科学）

    2019年度

  • 演習（医薬品開発規制科学）

    2019年度

  • 卒業研究Ａ

    2019年度

  • 実務実習事前学習（実習）

    2019年度

  • 薬学英語演習Ｏ

    2019年度

全件表示 >>

このページの先頭へ▲